Related Experiment Video
Updated: Jan 27, 2026

Transcranial Direct Current Stimulation tDCS in Mice
Published on: September 23, 2018
Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy
Bradley A McGregor1, Guru P Sonpavde1
1Genitourinary Oncology Division, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Abstract:
Treatment options for rare genitourinary malignancies, including adrenocortical carcinoma, bladder/upper tract cancers of variant histology, penile squamous cell carcinoma, and chemotherapy-refractory germ cell tumors, are limited, often with a poor response to systemic therapy. Given preclinical data and efficacy across multiple malignancies, immunotherapy has been and continues to be explored in this challenging setting. In this report, we explore the data for immunotherapy in these tumors and highlight ongoing clinical trials. International collaborations and innovative trials will be critical to advancing treatment for these rare tumors. PATIENT SUMMARY: In this report, we explore the data for immunotherapy in rare genitourinary malignancies and highlight ongoing clinical trials. International collaborations and innovative trials will be critical to advancing treatment for these rare tumors.
Insights
Immunotherapy shows promise for rare genitourinary cancers like adrenocortical carcinoma and penile cancer. Ongoing clinical trials and international collaboration are crucial for advancing treatment options for these difficult-to-treat diseases.
Area of Science:
- Genitourinary Oncology
- Cancer Immunotherapy
- Rare Cancers
Background:
- Limited effective systemic therapies exist for rare genitourinary malignancies.
- Preclinical data and efficacy in other cancers suggest immunotherapy potential.
- Adrenocortical carcinoma, variant histology bladder/upper tract cancers, penile squamous cell carcinoma, and chemotherapy-refractory germ cell tumors represent challenging cases.
Purpose of the Study:
- To review current data on immunotherapy for rare genitourinary tumors.
- To highlight ongoing clinical trials in this area.
- To emphasize the need for international collaboration and innovative trial designs.
Main Methods:
- Review of preclinical data and clinical trial results for immunotherapy in rare genitourinary malignancies.
- Identification and summary of ongoing clinical trials.
- Discussion of challenges and future directions.
Main Results:
- Immunotherapy is being actively explored in rare genitourinary cancers.
- Efficacy data, though limited, supports further investigation.
- Numerous clinical trials are underway to evaluate various immunotherapeutic agents.
Conclusions:
- Immunotherapy represents a promising avenue for treating rare genitourinary malignancies.
- International collaboration and innovative clinical trials are essential for progress.
- Further research is needed to optimize immunotherapy strategies for these patient populations.
Related Concept Videos
Tumor Immunotherapy
Anatomy of the Genitourinary System II: Bladder and Urethra
Marcia's Theory of Identity Status
Electrical Current
Anatomy of the Genitourinary System I: Kidneys and Ureters
Physiology of the Genitourinary System III: Urine Concentration and Dilution

